obesity research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
eat-me signal A molecule exposed on the surface of a cell which effectively tags the cell for phagocytosis, inducing phagocytes to engulf or "eat" it. The presence of oxidized phospholipids or phosphatidylserine, or the absence of sialic acid from cell surface glycoproteins or glycolipids, are all commonly used as eat-me signals in certain cell types. See also find-me signal.
Morphine, formerly known as morphium, is an opiate found naturally in opium, a dark brown resin produced by drying the latex of opium poppies (Papaver somniferum). It is mainly used as an analgesic (pain medication). There are multiple methods used to administer morphine: oral; sublingual; via inhalation; injection into a muscle, injection under the skin, or injection into the spinal cord area; transdermal; intravenously; or via rectal suppository. It acts directly on the central nervous system (CNS) to induce analgesia and alter perception and emotional response to pain. Physical and psychological dependence and tolerance may develop with repeated administration. It can be taken for both acute pain and chronic pain and is frequently used for pain from myocardial infarction, kidney stones, and during labor. Its maximum effect is reached after about 20 minutes when administered intravenously and 60 minutes when administered by mouth, while the duration of its effect is 3–7 hours. Long-acting formulations of morphine are sold under the brand names MS Contin and Kadian, among others. Generic long-acting formulations are also available. Common side effects of morphine include drowsiness, euphoria, nausea, dizziness, sweating, and constipation. Potentially serious side effects of morphine include decreased respiratory effort, vomiting, and low blood pressure. Morphine is highly addictive and prone to abuse. If one's dose is reduced after long-term use, opioid withdrawal symptoms may occur.
== Regulation == In the US, in January 2004, the FDA granted permission to produce and market maggots for use in humans or animals as a prescription-only medical device for the following indications: "For debriding non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds."
=== Single-brand retail reforms approved === On 11 January 2012, India approved increased competition and innovation in single-brand retail. The reform seeks to attract investments in operations and marketing, improve the availability of goods for the consumer, encourage increased sourcing of goods from India, and enhance competitiveness of Indian enterprises through access to global designs, technologies and management practices. In this announcement, India requires single-brand retailer, with greater than 51% foreign ownership, to source at least 30% of the value of products from Indian small industries, village and cottage industries, artisans and craftsmen. Mikael Ohlsson, chief executive of IKEA, announced IKEA is postponing its plan to open stores in India. He claimed that IKEA's decision reflects India's requirements that single-brand retailers such as IKEA source 30 percent of their goods from local small and medium-sized companies. This was an obstacle to IKEA's investment in India, and that it will take IKEA some time to source goods and develop reliable supply chains inside India. Ikea announced that it plans to double what it sources from India already for its global product range, to over $1 billion a year, within three years. IKEA in the near term, plans to focus expansion instead in China and Russia, where such restrictions do not exist. On 19 Feb 2013 Tamil Nadu became the first state in the country to stoutly resist MNC 'invasion' into the domestic retail sector.
Only six years later, Hurricane Hattie struck the central coastal area of the country, with winds in excess of 300 km/h (185 mph) and 4 m (13 ft) storm tides. The devastation of Belize City for the second time in thirty years prompted the relocation of the capital some 80 kilometres (50 mi) inland to the planned city of Belmopan. In 1978, Hurricane Greta caused more than US$25 million in damage along the southern coast. In 2000, Hurricane Keith, the wettest tropical cyclone in the nation's record, stalled, and hit the nation as a Category 4 storm on 1 October, causing 19 deaths and at least $280 million in damage. Soon after, on 9 October 2001, Hurricane Iris made landfall at Monkey River Town as a 235 km/h (145 mph) Category 4 storm. The storm demolished most of the homes in the village, and destroyed the banana crop. In 2007, Hurricane Dean made landfall as a Category 5 storm only 40 km (25 mi) north of the Belize–Mexico border. Dean caused extensive damage in northern Belize. In 2010, Belize was directly affected by the Category 2 Hurricane Richard, which made landfall approximately 32 kilometres (20 mi) south-southeast of Belize City at around 00:45 UTC on 25 October 2010. The storm moved inland towards Belmopan, causing estimated damage of BZ$33.8 million ($17.4 million 2010 USD), primarily from damage to crops and housing. The most recent hurricane to make landfall in Belize was Hurricane Lisa in 2022. Extreme weather events, such as hurricanes and floods, have become more frequent and intense due to climate change.
Sources: en.wikipedia.org
== Diagnosis == There is no consensus standard for diagnosing carpal tunnel syndrome. A combination of characteristic symptoms (how it feels) and signs (what the clinician finds on exam) is associated with a high probability of CTS without electrophysiological testing. Sensation loss can be established using Semmes-Weinstein monofilament testing. CTS can be detected on examination using one of several maneuvers to provoke paresthesia (a sensation of tingling or "pins and needles" in the median nerve distribution). These so-called provocative signs include:
A secondary-ion mass spectrometer consists of (1) a primary ion gun generating the primary ion beam, (2) a primary ion column, accelerating and focusing the beam onto the sample (and in some devices an opportunity to separate the primary ion species by Wien filter or to pulse the beam), (3) high-vacuum sample chamber holding the sample and the secondary-ion extraction lens, (4) a mass analyzer separating the ions according to their mass-to-charge ratios, and (5) a detector.
A refrigerator, commonly shortened to fridge, is a commercial and home appliance consisting of a thermally insulated compartment and a heat pump (mechanical, electronic, or chemical) that transfers heat from its inside to its external environment so that its inside is cooled to a temperature below the ambient temperature of the room. Refrigeration is an essential food storage technique around the world. The low temperature reduces the reproduction rate of bacteria, so the refrigerator lowers the rate of spoilage. A refrigerator maintains a temperature a few degrees above the freezing point of water. The optimal temperature range for perishable food storage is 3 to 5 °C (37 to 41 °F). A freezer is a specialized refrigerator, or portion of a refrigerator, that maintains its contents' temperature below the freezing point of water. The refrigerator replaced the icebox, which had been a common household appliance for almost a century and a half. The United States Food and Drug Administration recommends that the refrigerator be kept at or below 4 °C (40 °F) and that the freezer be regulated at −18 °C (0 °F). The first cooling systems for food involved ice. Artificial refrigeration began in the mid-1750s, and developed in the early 1800s. In 1834, the first working vapor-compression refrigeration system, using the same technology seen in air conditioners, was built. The first commercial ice-making machine was invented in 1854. In 1913, refrigerators for home use were invented. In 1923 Frigidaire introduced the first self-contained unit.
The Vietnam era saw the testing and shaping of Special Forces policy and action for the United States. The mission of the Special Forces changed rapidly in the first years from a force that had initially been used like its WWII predecessors as an internal strike force into a training force which helped develop unconventional warfare and counterinsurgency tactics. The period between 1961 and 1965 was especially formative. The first U.S. Special Forces operations in Vietnam were in 1957, when soldiers from the 1st Special Forces Group trained fifty-eight Vietnamese Army soldiers at the Commando Training Center in Nha Trang. Special Forces units deployed to Laos as "Mobile Training Teams" (MTTs) in 1961, Project White Star (later named Project 404), and they were among the first U.S. troops committed to the Vietnam War. Beginning in the early 1950s, Special Forces teams deployed from the United States and Okinawa to serve as advisers for the fledgling South Vietnamese Army. As the United States escalated its involvement in the war, the missions of the Special Forces expanded as well. Since Special Forces were trained to lead guerrillas, it seemed logical that they would have a deep understanding of counter-guerrilla actions, which became the Foreign Internal Defense (FID) mission. The 5th Special Forces Group mixed the UW and FID missions, often leading Vietnamese units such as Montagnards and lowland Civilian Irregular Defense Groups. The deep raid on Son Tay, attempting to recover U.S. prisoners of war, had a ground element completely made up of Special Forces soldiers.
Sources: en.wikipedia.org
=== N05BA Benzodiazepine derivatives === N05BA01 Diazepam N05BA02 Chlordiazepoxide N05BA03 Medazepam N05BA04 Oxazepam N05BA05 Dipotassium clorazepate N05BA06 Lorazepam N05BA07 Adinazolam N05BA08 Bromazepam N05BA09 Clobazam N05BA10 Ketazolam N05BA11 Prazepam N05BA12 Alprazolam N05BA13 Halazepam N05BA14 Pinazepam N05BA15 Camazepam N05BA16 Nordazepam N05BA17 Fludiazepam N05BA18 Ethyl loflazepate N05BA19 Etizolam N05BA21 Clotiazepam N05BA22 Cloxazolam N05BA23 Tofisopam N05BA24 Bentazepam N05BA25 Mexazolam N05BA26 Oxazolam N05BA27 Metaclazepam N05BA56 Lorazepam, combinations
== Research and contributions == Sheiner's research focused on developing mathematical models and data analysis techniques to quantitatively characterize the impact of drug therapy from observational data, gathered either during drug development trials or during routine patient care. The practical objective motivating his research was more efficient and informative clinical trials as well as the ability to optimize dosage recommendations for individual patients. His work has influenced clinical pharmacology as a scientific discipline as well as the pharmaceutical industry and drug regulation more broadly. Sheiner's models have been implemented via software such as NONMEM, co-developed with Barr Rosenberg. Among his many notable papers are "Modelling of individual pharmacokinetics for computer-aided drug dosage" in 1972, "Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models" co-written with Nick Holford in 1981, and "Learning versus confirming in clinical drug development" in 1997.
== Detection == The first line of defense in preventing chronic Somogyi rebound is additional blood glucose testing. Continuous glucose monitoring is the preferred method to detect and prevent the Somogyi rebound, but this technology is far from universally used. Alternatively, testing blood sugar more often, 8 to 10 times daily with a traditional blood glucose meter, facilitates detecting the low blood sugar level before such a rebound occurs. Testing occasionally during the middle of the night is also important, particularly when high waking blood sugars are found, to determine if more insulin is needed to prevent hyperglycemia or if less insulin is needed to prevent such a rebound. Sometimes a person with diabetes will experience the Somogyi rebound when awake and notice symptoms of the initial low blood sugar or symptoms of the rebound. Waking with a night sweat (perhaps combined with a rapid heart rate) is a symptom of the adrenaline and rebound. Unfortunately, the evidence shows that patients with type 1 diabetes do not normally wake during nocturnal hypoglycemic episodes. While reviewing log data of blood glucose after the fact, signs of Somogyi rebound should be suspected when blood glucose numbers seem higher after the insulin dosage has been raised, particularly in the morning. One simple way to determine if nocturnal hypoglycemia may be causing morning hyperglycemia is to have the patient have a high protein snack with a small amount of carbohydrates at bedtime. This will help keep the blood sugar up overnight and prevent the Somogyi effect.
Features of the Advanced Lesion: Extension of the lesion into alveolar bone, periodontal ligament with significant bone loss Continued loss of collagen Cytopathic alterations in plasma cells in the absence of altered fibroblasts Formation of periodontal pocketing Conversion of bone marrow into fibrous connective tissue
=== Pharmacokinetics === Lorazepam is highly protein-bound and is extensively metabolized into pharmacologically inactive metabolites. Due to its poor lipid solubility, lorazepam is absorbed relatively slowly by mouth and is unsuitable for rectal administration. However, its poor lipid solubility and a high degree of protein binding (85–90%) mean that its volume of distribution is mainly the vascular compartment, causing relatively prolonged peak effects. This contrasts with the highly lipid-soluble diazepam, which, although rapidly absorbed orally or rectally, soon redistributes from the serum to other parts of the body, in particular, body fat. This explains why one lorazepam dose, despite its shorter serum half-life, has more prolonged peak effects than an equivalent diazepam dose. Lorazepam is rapidly conjugated at its 3-hydroxy group into lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide has no demonstrable CNS activity in animals. The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to six months. On regular administration, diazepam will accumulate, since it has a longer half-life and active metabolites, these metabolites also have long half-lives.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.